Industry Outlook 2025: Shifting Political Landscapes

After the results of the Presidential elections in the United States towards the end of 2024, there have been a lot of speculations about what impact the changing political landscape may have on many industries, including the bio/pharma industry. “The two big things that have happened in the US from a legislative point of view, the Inflation Reduction Act and BIOSECURE act, you know that they've blown a pretty cold wind through the industry,” says Adam Sherlock, CEO of Qinecsa, a pharmacovigilance technology and services solution provider. “So, one question is going to be, will [those things] continue to impact [the industry], and I suspect [they] will, because I don't sense that [they will] be rolled back. The biggest unknown, of course, is what's going to be the direction of travel of the incoming administration?”

It isn’t only the US that has undergone governmental shifts, however, as 2024 was also a key election year for Europe. “[In] Europe, we've got an increasingly aging but long living population,” Sherlock remarks. “So, I see the fundamental issue in Europe [as] downward price pressure […] on price, on industry, and at the same time medicine being required to deliver innovation and new therapies to treat longer living, older people with more complex needs, or just, in general, the population with more complex needs. How do you square those two things that that fundamental tension in the system doesn't change whether, you know, irrespective of the political hue of the of whichever government of whichever member state, we've got the same problem.”

Click above to watch the full interview

About the speaker

Adam Sherlock is CEO of Qinecsa Solutions, which is a UK headquartered, international pharmacovigilance technology and services solution provider. Adam has more than 35 years’ experience within the pharma services industry and has held senior roles in a number of different pharma services businesses over the past 15 years.